JP Morgan Healthcare Conference and Biotech Showcase 2025
While most will agree that change is inevitable, what we’re seeing play out in the biopharma market is a game-changing transition of an unparalleled degree. Difficult capital markets, the Inflation Reduction Act (IRA), rising costs and sinking returns means the path to commercializing an asset looks very different and is much more difficult. The level of preparation required to succeed is far greater and the market ask is different.
By leveraging our resources and expertise spanning all clinical development, medical affairs and commercialization, you will be able to:
- Optimize clinical development processes through more informed trial design and RWE strategies
- Realize better pipeline portfolio management
- Leverage the predictive power of data & analytics to inform your decision-making
Meet with Us
Our experts will be on the ground in San Francisco during the JP Morgan Healthcare Conference, and Biotech Showcase: The Investor Conference for Innovators to discuss your specific asset challenges and how we can drive success across the asset development continuum, providing fit-for-purpose solutions with high-quality delivery.
Featured Sessions
LUNCHEON PLENARY PANEL | The "New” Policy Landscape: Now that the Election is Behind Us, Where Do We Go from Here?
January 13 | 12-1:30pm PT
Join us for a discussion on the Inflation Reduction Act (IRA), the decision to overturn Chevron deference, and other issues that are impacting the healthcare landscape. This panel of experts will explore how these pivotal changes could reshape regulatory environments, funding opportunities and innovation.
Tony Lanzone, Global Head, Consulting, Syneos Health
PANEL | Dealmakers’ Intentions 2025
January 13 | 3:30-4:30pm PT
This session will discuss the results of this year’s Dealmakers’ Intentions Survey, providing a prospective view of the partnering and licensing landscape for the year ahead. Now in its 16th year, this survey provides a unique perspective on these trends by surveying business development professionals from pharmaceutical and biotechnology companies of all sizes to create forward-looking insights based on dealmakers' general expectations for activity in the coming year.
Katya Magonova, Managing Director, Commercial Advisory, Syneos Health
PANEL | Investing In the TechBio Space: A Huge Impact on Therapeutic Development & A Shorter Time Frame to Revenue
January 14 | 10:00-11:00am PT
TechBio companies generate revenue by providing services that enable and enhance drug and diagnostic development. They are not hindered by the long approval process and potential failures of the drug development that biotech companies face.
Michael Sarshad, Managing Director, Commercial Advisory, Syneos Health
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Driving Commercial Success with Predictive Analytics and Agile Resourcing
The Key to Accelerated Global Expansion: Adaptability through a Flexible Outsourcing Model
Untapped Potential in Women’s Health: An Analysis of Gender Imbalance in Life Science Investment
WEBINAR | Adaptability: The Key to Accelerated Global Expansion
VIDEO | AI, Market Trends and Strategic Planning in Biotech
COMING SOON! 2025 Health Trends
COMING SOON! Dealmakers’ Intentions 2025
